English 
Neuromyelitis Optica Spectrum Disorder (NMOSD) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00
Description
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an inflammatory, demyelinating, antibody-mediated disease of the central nervous system (CNS) that predominantly targets the optic nerves, brainstem, and spinal cord. The NMOSD involves the aquaporin 4 (AQP4) which is a membrane-bound protein with a high concentration in a certain region of the central nervous system, such as the optic nerve, the spinal cord which is being attacked by the IgG antibody.
Neuromyelitis Optica Spectrum Disorder (NMOSD)– Epidemiology
NMOSD can be categorized into two pathophysiological entities depending on the presence or absence of AQP4-Ab. In approx. 80% of cases, AQP4-Ab can be detected, which cause a primarily astrocytopathic disease. Interestingly, in about 50% of the AQP4-Ab seronegative NMOSD patients autoantibodies against myelin-oligodendrocyte-glycoprotein (MOG-Ab) can be seen, whose pathomorphological correlate is primarily oligodendrocytopathic.AQP4-IgG testing in cases with good clinical reason to suspect NMOSD may be of value and that a positive AQP4-IgG test lessens the clinical and radiologic requirements for a diagnosis of NMOSD; these principles guided the development of the diagnostic criteria proposed by the IPND. The 2015 diagnostic criteria outline a stratified diagnosis based on the presence or absence of serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG), which are highly specific for NMOSD. Most—though not all—patients with NMO have detectable serum antibodies that target AQP4-IgG.
As per estimates, the United States accounted for the highest prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD) cases are expected to reach ~18,000 by 2032 during the study period.
Neuromyelitis Optica Spectrum Disorder (NMOSD)– Current Market Size & Forecast Trends
The current therapies market to treat Neuromyelitis Optica Spectrum Disorder (NMOSD) has transformed in recent years with new options for a disease that that have the potential to significantly improve patient outcomes. In countries where all three of these new treatments are approved for clinical use, clinicians are now faced with a changing landscape of options to offer their patients with NMOSD, who might have different priorities among efficacy, safety, cost, monitoring burden, and logistics. The current therapies market to treat NMOSD is large as 100% of the affected population will be prescribed with immunosuppressive agents as first line of therapy.
Currently, three medications have been approved for the treatment of NMOSD and these include satralizumab, eculizumab and inebilizumab. These medications have shown promising results concerning short-term efficacy. However, there is no data on long-term safety and efficacy in NMOSD patients and their efficacy in AQP4-Ab negative NMOSD patients is not yet known. At present, drugs such as azathioprine, rituximab and mycophenolate mofetil are being used to prevent relapse for patients with NMOSD. However, recurrent relapse in patients with NMOSD is still common which is due to the lack of specific therapeutic target. Additionally, some patients are intolerable to certain treatments due to their side effects, such as avascular necrosis of femoral head and hepatic impairment.
The Neuromyelitis Optica Spectrum Disorder (NMOSD) therapy market is expected to experience high growth throughout our study period, increasing from ~USD 400 million in 2018 to USD XX billion in 2032. The primary drivers of this growth will be the uptake of the existing drugs i.e. Soliris/Eculizumab (Alexion), Enspryng/Satralizumab (Roche) and Uplinza/Inebilizumab (Horizon) as well as the launch of the new drugs i.e., Ravulizumab (Alexion) Telitacicept (RemeGen).
Report Highlights
- Neuromyelitis Optica Spectrum Disorder (NMOSD) – Current Market Trends
- Neuromyelitis Optica Spectrum Disorder (NMOSD) – Current & Forecasted Cases across the G7 Countries
- Neuromyelitis Optica Spectrum Disorder (NMOSD) – Market Opportunities And Sales Potential for Agents
- Neuromyelitis Optica Spectrum Disorder (NMOSD) – Patient-based Market Forecast to 2032
- Neuromyelitis Optica Spectrum Disorder (NMOSD) – Untapped Business Opportunities
- Neuromyelitis Optica Spectrum Disorder (NMOSD) – Product Positioning Vis-a-vis Competitors’ Products
- Neuromyelitis Optica Spectrum Disorder (NMOSD) – KOLs Insight
Additional information
| Price | Single User License, 2-3 User License, Site License, Enterprise License |
|---|
Table of Contents
- Executive Summary
- Key Findings
- Neuromyelitis Optica Spectrum Disorder (NMOSD) Disease Background
- Neuromyelitis Optica Spectrum Disorder (NMOSD): Key Highlights
- Definition
- Symptoms & Causes
- Classifications
- Pathophysiology
- Pathophysiologic Mechanisms and Therapeutic Targets in NMOSD
- Diagnosis
- Epidemiology Estimated and Forecast to 2032
- Key Findings
- Methods and data Sources
- Country Specific Prevalent Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD) (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Specific Acute & Chronic Treated Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Country Specific Chronic Refractory/Relapsed (R/R) Prevalent cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Key Sources for Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology and Model Parameters
- United States
- United States Prevalent Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- United States Acute & Chronic Treated Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- United States Chronic Refractory/Relapsed (R/R) Prevalent cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Germany
- Germany Prevalent Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Germany Acute & Chronic Treated Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Germany Chronic Refractory/Relapsed (R/R) Prevalent cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- France
- France Prevalent Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- France Acute & Chronic Treated Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- France Chronic Refractory/Relapsed (R/R) Prevalent cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Italy
- Italy Prevalent Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Italy Acute & Chronic Treated Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Italy Chronic Refractory/Relapsed (R/R) Prevalent cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Spain
- Spain Prevalent Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Spain Acute & Chronic Treated Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Spain Chronic Refractory/Relapsed (R/R) Prevalent cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- United Kingdom
- United Kingdom Prevalent Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- United Kingdom Acute & Chronic Treated Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- United Kingdom Chronic Refractory/Relapsed (R/R) Prevalent cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Japan
- Japan Prevalent Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Japan Acute & Chronic Treated Cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Japan Chronic Refractory/Relapsed (R/R) Prevalent cases of Neuromyelitis Optica Spectrum Disorder (NMOSD)
- United States
- Current Therapies and Medical Practice
- Treatments & Medical Practices
- NMOSD Treatment Algorithm
- Marketed Drug
- Eculizumab (Alexion Pharmaceuticals)
- Satralizumab (Roche)
- Inebilizumab (Horizon Therapeutics/Viela Bio)
- Unmet Needs
- Emerging Therapies
- Pipeline Overview
- Therapeutic Developments Pipeline for Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Product Analysis
- Ravulizumab (Alexion Pharmaceuticals)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Telitacicept (RC-Pharma)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- SHR1459 (Reistone Biopharma)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- BAT4406F (Bio-Thera Solutions)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Batoclimab (Harbour BioMed)
- Product Profile
- Clinical Development
- XT-0528 (Xenter Therapeutics/Arrien Pharmaceuticals/Boston Pharmaceuticals)
- Product Profile
- Clinical Development
- Ublituximab (TG Therapeutics)
- Product Profile
- Clinical Development
- Lu AG06466 (Lundbeck/Abide Therapeutics)
- Product Profile
- Clinical Development
- CRD1 (Chord Therapeutics)
- Product Profile
- Ravulizumab (Alexion Pharmaceuticals)
- Product Analysis
- Neuromyelitis Optica Spectrum Disorder (NMOSD)- Cost Burden & Prescriptions survey
- Future Treatment Paradigm
- Neuromyelitis Optica Spectrum Disorder (NMOSD) Competitor Landscape and Approvals Anticipated
- Future Treatment Algorithms and Competitor Positioning
- Key Data Summary for Emerging Treatment
- Annual Cost of Current & Emerging Therapies
- Market Outlook
- Key Findings
- Country Specific Market Forecast to 2032
-
-
- G7 total Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) 2022-2032 (USD Million)
- G7 total Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) by Therapies 2022-2032 (USD Million)
-
- Market Forecast by Country
- United States
- United States Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) 2022-2032 (USD Million)
- United States Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) by Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) 2022-2032 (USD Million)
- Germany Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) by Therapies 2022-2032 (USD Million)
- France
- France Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) 2022-2032 (USD Million)
- France Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) by Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) 2022-2032 (USD Million)
- Italy Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) by Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) 2022-2032 (USD Million)
- Spain Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) by Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) 2022-2032 (USD Million)
- United Kingdom Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) by Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) 2022-2032 (USD Million)
- Japan Market for Neuromyelitis Optica Spectrum Disorder (NMOSD) by Therapies 2022-2032 (USD Million)
- United States
- Market Drivers and Constraints
- What Factors Are Driving the Market for Neuromyelitis Optica Spectrum Disorder (NMOSD)?
- What Factors Are Constraining the Market for Neuromyelitis Optica Spectrum Disorder (NMOSD)?
- Appendix
Sample Enquiry
Related products
-
Lumbar Radiculopathy (Sciatica)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Lumbar Radiculopathy/LSR (Sciatica) therapeutic market is expected to experience high growth throughout our study period, increasing from 2017 to 2030. The main drivers of this growth will be the launch of new drugs in chronic LSR/sciatica setting, e.g., Dexamethasone sodium phosphate gel / SEMDEXA (Scilex Pharmaceuticals), Condoliase / HERNICORE (Seikagaku Corporation / Ferring Pharmaceuticals), ETX-810 (Eliem Therapeutics Inc), Extended-release Clonidine / Clonidine micropellet (Sollis Therapeutics) and extended-release dexamethasone (SpineThera).
-
Acute Kidney Injury (AKI) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the incidence AKI population will contribute to increasing sales in the AKI therapy market over our forecast period. An estimated annual growth rate of 2.68% in the diagnosed incident AKI population across the major pharmaceutical markets will contribute to increasing AKI therapy sales. In 2019, there were approximately 1.95 million diagnosed cases of AKI in the major markets; we expect the number of cases will exceed 2 million in 2032 owing to changes in population demographics and increasing cases of AKI associated conditions such as sepsis-AKI, Cardiac surgery-associated AKI and others.
The continuous involvement of supportive treatments including renal replacement therapies for the management of AKI patients will contribute to the the overall growth of the AKI therapy market. We forecast that total sales of the total care market will reach $XX billion by 2032.
-
Corticobasal Syndrome (CBS) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsCorticobasal syndrome (CBS) is characterized by lowest clinical diagnostic accuracy, with the highest clinical presentation found in corticobasal degeneration (CBD). Current Corticobasal syndrome (CBS) treatment is limited to levodopa, commonly prescribed medication for the treatment of Parkinson’s disease. Thus, there is a huge unmet need for a medical treatment to improve the quality of life. Emerging therapies like Rho-kinase inhibitor- Fasudil (Woolsey Pharmaceuticals) have the potential to overcome the treatment barrier. Corticobasal syndrome market size will reflect high growth from 2025-2030 due to launch of Fausdil (Woolsey) in the market from 2025 year.
-
Head and neck squamous cell carcinoma (HNSCC)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2033
$7,500.00 – $22,500.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the Head and neck squamous cell carcinoma (HNSCC) therapeutics market for HNSCC s was worth US$ Billion in 2023 and is predicted to grow at a 13.9% CAGR to reach US$ 7.5 Billion by 2033.